Shanghai Center, PerkinElmer To Tie In Targeting Chinese Diabetes Cases
This article was originally published in PharmAsia News
Executive Summary
U.S.-based PerkinElmer has signed an agreement with the Shanghai-based National Center for Drug Screening to develop personalized drugs and profiling for diabetes patients.